Endocrine Pharmacology Practice Questions

Q: Octreotide is indicated in all of the following conditions except?

Infective diarrhea. **Explanation:** **Octreotide** is a synthetic long-acting analogue of **Somatostatin**. It acts as a potent inhibitor of various physiological processes, including the secretion of growth hormone, insulin, glucagon, and gastrointestinal hormones. **Why Option C is the Correct Answer:** Octreotide is **not indicated** in infective diarrhea. In cases of infection (e.g., Cholera, Shigella), the body’s primary mechanism to clear the pathogen is through intestinal motility and secretion. Octreotide inhibits intestinal motility and secretion, which can lead to the retention of toxins and pathogens, potentially worsening the clinical condition. Management of infective diarrhea focuses on rehydration and appropriate antimicrobial therapy. **Analysis of Incorrect Options:** * **A. Bleeding Esophageal Varices:** Octreotide causes **splanchnic vasoconstriction** (by inhibiting vasodilatory hormones like glucagon). This reduces portal venous pressure and helps control variceal bleeding. * **B. Secretory Diarrhea:** It is highly effective in treating secretory diarrhea associated with **VIPomas, Carcinoid syndrome, and HIV/AIDS**, as it inhibits the secretion of water and electrolytes into the gut lumen. * **D. Acromegaly:** As a somatostatin analogue, it directly inhibits the release of **Growth Hormone (GH)** from the anterior pituitary, making it a first-line medical therapy for acromegaly. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Agonist at somatostatin receptors (SSTR-2 and SSTR-5). * **Other Indications:** Glucagonoma, Gastrinoma (Zollinger-Ellison Syndrome), and dumping syndrome. * **Side Effects:** Biliary sludge and **gallstones** (due to inhibition of cholecystokinin and gallbladder contraction), steatorrhea, and nausea. * **Diagnostic Use:** Radiolabeled octreotide (OctreoScan) is used for localizing neuroendocrine tumors.

Q: Which of the following anti-diabetic drugs can be used safely in renal failure?

Linagliptin. **Explanation:** The correct answer is **Linagliptin**. The primary medical concept here is the **route of elimination**. Most oral hypoglycemic agents (OHAs) are excreted renally, requiring dose adjustments or discontinuation as the Glomerular Filtration Rate (GFR) declines to prevent drug accumulation and toxicity. **Why Linagliptin is correct:** Linagliptin is a DPP-4 inhibitor characterized by a unique **non-renal (primarily biliary/fecal) excretion** pathway. Approximately 90% of the drug is excreted unchanged in the feces. Therefore, it is the only DPP-4 inhibitor that requires **no dose adjustment** across all stages of renal impairment, including end-stage renal disease (ESRD). **Why the other options are incorrect:** * **Metformin:** It is excreted unchanged by the kidneys. It is contraindicated when eGFR is <30 mL/min due to the high risk of **lactic acidosis**. * **Sitagliptin:** While also a DPP-4 inhibitor, it is primarily excreted renally. It requires significant dose reductions as renal function declines. * **Canagliflozin:** As an SGLT-2 inhibitor, its efficacy depends on filtered glucose load. It is generally not initiated if eGFR is <30 mL/min and is less effective as renal function worsens. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** Remember **"L"** in **L**inagliptin stands for **L**iver (Biliary) excretion. * **Safe in Renal Failure:** Other OHAs safe in renal failure include **Pioglitazone** (metabolized by liver) and **Repaglinide** (primarily fecal excretion). * **Insulin:** In advanced renal failure, insulin requirements actually *decrease* because the kidney is a site for insulin degradation. * **DPP-4 Inhibitors:** All end in the suffix **"-gliptin."** Except for Linagliptin, all require renal dose adjustment.

Q: Which of the following agents has the lowest risk of causing nausea and vomiting?

Albiglutide. **Explanation:** The question focuses on the side effect profile of **GLP-1 Receptor Agonists (GLP-1 RAs)**. Nausea and vomiting are the most common adverse effects of this class, occurring due to delayed gastric emptying and direct activation of the area postrema in the CNS. **Why Albiglutide is Correct:** The incidence of gastrointestinal (GI) side effects is largely determined by the **pharmacokinetics** and **molecular size** of the agent. * **Albiglutide** is a long-acting GLP-1 RA consisting of two GLP-1 molecules fused to **human albumin**. * Its large molecular size limits its penetration across the blood-brain barrier into the vomiting centers. * Clinical trials (e.g., HARMONY trials) demonstrated that Albiglutide has a significantly lower rate of nausea (approx. 10%) compared to other agents in its class. **Analysis of Incorrect Options:** * **Lixisenatide:** A short-acting agent. Short-acting GLP-1 RAs cause more pronounced inhibition of gastric emptying, leading to higher rates of acute nausea. * **Semaglutide & Liraglutide:** These are potent GLP-1 RAs. While highly effective for glycemic control and weight loss, they are associated with a higher incidence of GI distress (up to 20-40%), especially during the dose-escalation phase. **High-Yield Clinical Pearls for NEET-PG:** * **Weight Loss Potency:** Semaglutide > Liraglutide > Dulaglutide > Exenatide > Albiglutide. (Albiglutide is less effective for weight loss). * **Renal Safety:** Liraglutide is generally preferred in mild-to-moderate renal impairment; Exenatide must be avoided if CrCl <30 mL/min. * **Black Box Warning:** All GLP-1 RAs carry a risk of **Medullary Thyroid Carcinoma (MTC)** and are contraindicated in patients with Multiple Endocrine Neoplasia (MEN) type 2. * **Note:** Albiglutide was discontinued by the manufacturer (GSK) for commercial reasons, but it remains a high-yield "concept" question regarding side-effect profiles.

Q: Which of the following is the most potent glucocorticoid?

Betamethasone. The potency of glucocorticoids is determined by their affinity for the glucocorticoid receptor and their duration of action. Glucocorticoids are generally classified into short, intermediate, and long-acting agents based on their anti-inflammatory potency relative to cortisol (hydrocortisone). **Why Betamethasone is correct:** Betamethasone and Dexamethasone are **long-acting glucocorticoids** with the highest anti-inflammatory potency. They are approximately **25–30 times more potent** than hydrocortisone. They also possess minimal to no mineralocorticoid (salt-retaining) activity, making them ideal for conditions where high-dose steroid therapy is required without causing fluid retention. **Analysis of Incorrect Options:** * **Hydrocortisone (A):** This is a short-acting steroid with a potency ratio of **1**. It is the pharmaceutical form of endogenous cortisol and possesses significant mineralocorticoid activity. * **Prednisolone (B):** This is an intermediate-acting steroid. It is approximately **4 times** more potent than hydrocortisone. * **Triamcinolone (D):** Also an intermediate-acting steroid, it is slightly more potent than prednisolone (about **5 times** more potent than hydrocortisone) but significantly less potent than betamethasone. **High-Yield NEET-PG Pearls:** 1. **Potency Hierarchy:** Betamethasone = Dexamethasone (25-30) > Triamcinolone (5) > Prednisolone (4) > Hydrocortisone (1). 2. **Fetal Lung Maturity:** Betamethasone is the preferred steroid to accelerate fetal lung maturity in preterm labor because it has better placental transfer and lower protein binding compared to other steroids. 3. **Mineralocorticoid Activity:** Long-acting steroids (Betamethasone/Dexamethasone) have **zero** mineralocorticoid activity, whereas Fludrocortisone has the highest. 4. **Topical Potency:** In topical formulations, Clobetasol propionate is considered one of the most potent (super-high potency) corticosteroids.

Q: Which non-steroidal anti-hormonal substance is used to induce ovulation?

Clomiphene citrate. **Explanation:** **Clomiphene Citrate (CC)** is the correct answer because it is a **Selective Estrogen Receptor Modulator (SERM)** that acts as a non-steroidal competitive antagonist of estrogen receptors in the hypothalamus and pituitary gland. By blocking the negative feedback of endogenous estrogen, it triggers an increase in the secretion of **GnRH, FSH, and LH**. The rise in FSH stimulates follicular growth in the ovaries, making it the first-line drug for ovulation induction in patients with PCOS (WHO Group II infertility). **Analysis of Incorrect Options:** * **Mifepristone (A):** A competitive progesterone receptor antagonist (and glucocorticoid antagonist). It is primarily used for medical abortion and emergency contraception, not for inducing ovulation. * **Tamoxifen (C):** While also a SERM and occasionally used off-label for ovulation induction in clomiphene-resistant cases, Clomiphene remains the classic, primary "non-steroidal anti-hormonal" drug associated with this indication in standard medical curricula. * **Raloxifene (D):** A second-generation SERM used primarily for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer. It does not play a role in ovulation induction. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Acts mainly by increasing **FSH** levels ("FSH window"). * **Administration:** Usually given as 50 mg/day for 5 days, starting on **Day 2 to Day 5** of the menstrual cycle. * **Side Effects:** Multiple pregnancy (10%, mostly twins), Ovarian Hyperstimulation Syndrome (OHSS), and anti-estrogenic effects on cervical mucus and endometrium. * **Hot Topic:** **Letrozole** (an Aromatase Inhibitor) is now considered superior to Clomiphene for ovulation induction in women with PCOS, though Clomiphene remains the classic textbook answer for this pharmacological category.

Q: Which of the following is not used for the treatment of insulin-induced hypoglycemia?

Adrenaline. The primary goal in treating insulin-induced hypoglycemia is to rapidly restore blood glucose levels to prevent neuroglycopenia. **Why Adrenaline is the Correct Answer:** While adrenaline (epinephrine) does increase blood glucose via glycogenolysis and gluconeogenesis, it is **not used clinically** to treat insulin-induced hypoglycemia. Its potent cardiovascular effects—such as severe tachycardia, arrhythmias, and hypertension—make it dangerous, especially in diabetic patients who may have underlying coronary artery disease. Furthermore, more effective and safer alternatives exist. **Analysis of Other Options:** * **Intravenous Glucose (Option A):** This is the **treatment of choice** for severe hypoglycemia in an unconscious patient or a hospital setting (typically 25-50% Dextrose). It provides an immediate source of glucose [2]. * **Glucagon (Option B):** Used as a first-line emergency treatment for severe hypoglycemia when IV access is unavailable [2]. It works by mobilizing hepatic glycogen stores [1]. (Note: It is ineffective in starved patients or those with liver disease due to depleted glycogen [1]). * **Oral Carbohydrates (Option C):** This is the preferred treatment for **conscious patients** who can swallow safely (the "15-15 rule": 15g of fast-acting carbs, recheck in 15 minutes) [2]. **NEET-PG High-Yield Pearls:** * **Drug of Choice (Severe Hypoglycemia):** IV Dextrose (25% or 50%) [2]. * **Glucagon Limitation:** It does not work in Type 1 diabetics with prolonged fasting or alcohol-induced hypoglycemia (depleted glycogen) [1]. * **Beta-Blockers Warning:** They can mask the autonomic symptoms of hypoglycemia (tachycardia, tremors) and delay recovery by inhibiting glycogenolysis. Sweating is the only symptom not masked (mediated by cholinergic fibers).

Q: Which of the following is a ligand for peroxisome proliferation activating receptor (PPAR), a group of nuclear hormone receptors involved in the regulation of genes related to glucose and lipid metabolism?

Rosiglitazone. **Explanation:** **Rosiglitazone** belongs to the **Thiazolidinedione (TZD)** class of oral hypoglycemic agents. These drugs act as selective ligands for the **Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ)**, a nuclear receptor primarily located in adipose tissue, muscle, and liver. Upon activation, PPAR-γ modulates the transcription of genes involved in glucose and lipid metabolism, leading to increased expression of glucose transporters (GLUT-4) and decreased insulin resistance. This "insulin-sensitizing" effect is their hallmark mechanism. **Analysis of Incorrect Options:** * **A. Repaglinide:** A Meglitinide analog that acts as an insulin secretagogue. It works by closing ATP-sensitive K⁺ channels on pancreatic beta cells, similar to Sulfonylureas, but at a different binding site. * **B. Voglibose:** An Alpha-glucosidase inhibitor. It acts locally in the intestine to inhibit the enzyme responsible for breaking down complex carbohydrates, thereby delaying glucose absorption and reducing postprandial hyperglycemia. * **C. Exenatide:** A Glucagon-like peptide-1 (GLP-1) agonist (Incretin mimetic). It enhances glucose-dependent insulin secretion and suppresses glucagon release. **High-Yield Clinical Pearls for NEET-PG:** * **PPAR-α vs. PPAR-γ:** While TZDs (Rosiglitazone, Pioglitazone) act on **PPAR-γ**, Fibrates (e.g., Fenofibrate) act on **PPAR-α** to lower triglycerides. Saroglitazar is a dual PPAR-α/γ agonist. * **Side Effects of TZDs:** Weight gain, **fluid retention/edema** (contraindicated in NYHA Class III/IV heart failure), and increased risk of bone fractures. * **Pioglitazone** has been specifically associated with a potential risk of bladder cancer (though controversial) and improves lipid profiles better than Rosiglitazone.

Q: Which DPP-IV inhibitor can be used in renal failure?

Linagliptin. **Explanation:** The correct answer is **Linagliptin**. **1. Why Linagliptin is correct:** The primary pharmacological distinction of Linagliptin among DPP-IV inhibitors is its route of elimination. Unlike most other gliptins, Linagliptin is primarily excreted via the **enterohepatic system (bile/feces)** rather than the kidneys. Approximately 90% of the drug is excreted unchanged in the feces. Therefore, it does not require dose adjustment in patients with any degree of renal impairment, making it the "gliptin of choice" for patients with chronic kidney disease (CKD). **2. Why the other options are incorrect:** * **Sitagliptin, Vildagliptin, and Saxagliptin:** These agents are predominantly excreted by the **kidneys**. In patients with renal failure, their clearance is reduced, leading to drug accumulation and increased risk of toxicity. While they *can* be used in renal failure, they require significant **dose reductions** based on the patient's Creatinine Clearance (CrCl). Linagliptin is unique because it is the only one that can be used at its standard dose (5 mg) regardless of renal function. **3. High-Yield Clinical Pearls for NEET-PG:** * **Saxagliptin Warning:** It is associated with an increased risk of hospitalization for **heart failure** (SAVOR-TIMI 53 trial). * **Vildagliptin:** It is the only common gliptin that requires twice-daily dosing and is associated with a risk of hepatotoxicity (monitor LFTs). * **DPP-IV Inhibitors Mechanism:** They inhibit the breakdown of GLP-1 and GIP, are weight-neutral, and carry a very low risk of hypoglycemia. * **Adverse Effect:** Always remember the association between DPP-IV inhibitors and **acute pancreatitis** and nasopharyngitis.

Question 1

Octreotide is indicated in all of the following conditions except?

Accepted Answer

Infective diarrhea

Answer

Bleeding esophageal varices

Answer

Secretory diarrhea

Answer

Acromegaly

Question 2

Which of the following anti-diabetic drugs can be used safely in renal failure?

Accepted Answer

Linagliptin

Answer

Metformin

Answer

Sitagliptin

Answer

Canagliflozin

Question 3

Which of the following conditions is NOT treated with Bromocriptine?

Accepted Answer

Endogenous depression

Answer

Parkinsonism

Answer

Prolactinoma

Answer

Infertility

Question 4

Which of the following agents has the lowest risk of causing nausea and vomiting?

Accepted Answer

Albiglutide

Answer

Semaglutide

Answer

Lixisenatide

Answer

Liraglutide

Question 5

Which of the following is the most potent glucocorticoid?

Accepted Answer

Betamethasone

Answer

Hydrocortisone

Answer

Prednisolone

Answer

Triamcinolone

Question 6

Which of the following drugs are used in the management of adrenal insufficiency?

Accepted Answer

Fludrocortisone

Answer

Hydrocortisone

Answer

Adrenaline

Answer

Dexamethasone

Question 7

Which non-steroidal anti-hormonal substance is used to induce ovulation?

Accepted Answer

Clomiphene citrate

Answer

Mifepristone

Answer

Tamoxifen

Answer

Raloxifene

Question 8

Which of the following is not used for the treatment of insulin-induced hypoglycemia?

Accepted Answer

Adrenaline

Answer

Intravenous glucose

Answer

Glucagon

Answer

Oral carbohydrates

Question 9

Which of the following is a ligand for peroxisome proliferation activating receptor (PPAR), a group of nuclear hormone receptors involved in the regulation of genes related to glucose and lipid metabolism?

Accepted Answer

Rosiglitazone

Answer

Repaglinide

Answer

Voglibose

Answer

Exenatide

Question 10

Which DPP-IV inhibitor can be used in renal failure?

Accepted Answer

Linagliptin

Answer

Sitagliptin

Answer

Vildagliptin

Answer

Saxagliptin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?